New treatment approach for complications of diabetes
Targeting RAGE/DIAPH1: Novel Therapeutic Strategy for Diabetic Complications
This study is exploring a new way to help people with diabetes heal wounds better and protect their kidneys by using special compounds that block a specific pathway in the body, and it aims to turn these findings into helpful treatments for diabetic patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10814272 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic strategy targeting the RAGE/DIAPH1 pathway to address complications associated with diabetes, such as impaired wound healing and kidney disease. The approach involves blocking the interaction between RAGE and DIAPH1, which is crucial for signaling related to these complications. Researchers have identified promising compounds that have shown efficacy in preclinical models, suggesting potential benefits for diabetic patients. The study aims to develop these compounds into effective treatments that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type 1 or type 2 diabetes who are experiencing complications such as impaired wound healing or diabetic nephropathy.
Not a fit: Patients without diabetes or those who do not have complications related to diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve healing and kidney function in diabetic patients.
How similar studies have performed: Other research has shown success in targeting similar pathways for diabetes complications, indicating that this approach has potential for meaningful advancements.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Schmidt, Ann Marie — New York University School of Medicine
- Study coordinator: Schmidt, Ann Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.